[Fotemustine: a pilot phase II trial in sarcoma of the soft tissues]

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Soft tissue sarcoma is a rare malignancy with limited treatment options for metastatic or recurrent disease.
• Fotemustine is a nitrosourea alkylating agent with potential antineoplastic activity.

Purpose of the Study:

• To evaluate the efficacy and safety of fotemustine in patients with metastatic or recurrent soft tissue sarcoma.
• To determine the optimal dosing and treatment schedule for fotemustine in this patient population.

Main Methods:

• A Phase II pilot study was conducted on 10 patients with metastatic or recurrent soft tissue sarcoma.
• Patients received fotemustine intravenously, with induction and maintenance phases, followed by rest periods.
• Efficacy was assessed by response evaluation at weeks 4 and 8, and toxicity was monitored throughout the study.

Main Results:

• One patient exhibited a minor response, and another showed disease stabilization, both of short duration.
• The primary toxicity was delayed hematological issues, specifically leucopenia and thrombopenia, with nadir at week 6.
• Fotemustine demonstrated limited efficacy in patients with a history of prior chemotherapy, according to statistical guidelines.

Conclusions:

• Fotemustine demonstrated minimal clinical benefit in patients with advanced soft tissue sarcoma, particularly those with prior chemotherapy exposure.
• Hematological toxicity, including delayed leucopenia and thrombopenia, is a significant concern with fotemustine treatment.
• Further investigation into fotemustine's role in soft tissue sarcoma treatment is warranted, potentially in different patient subgroups or combination therapies.